Since the early 1990s it has been postulated that hypofunction of N-methyl-Daspartate (NMDA) receptors in brain networks supporting perception and cognition underlies schizophrenic psychosis. Recently, NMDA receptor hypofunction was described in patients with psychotic manifestations who exhibited autoantibodies binding the GluN1 subunit of the receptor, and who improved when the level of these antibodies was lowered by immunomodulation. In this disorder, NMDA receptor antibodies decrease the availability of NMDA receptors by internalizing them. In this opinion article, we review this mechanism as well as data supporting or refuting the possibility that this disorder or similar autoimmune disorders affecting synaptic proteins, which are therefore treatable with immunomodulation, could account for some cases of idiopathic psychosis. We also suggest methodological approaches to clarify this issue.
Autoantibodies against the NMDA Receptor: Relevance to Psychotic Symptoms
Most excitatory neurotransmission in the brain is mediated by L-glutamate (see Glossary), an amino acid that activates several types of receptors, including the N-methyl-D-aspartate (NMDA) receptors (NMDARs). Most native NMDARs are heterotetramers composed of an obligatory GluN1 subunit and various combinations of GluN2 (A-D) and sometimes GluN3 A-B subunits, with various arrangements depending on developmental stage, function, and brain location [1] [2] [3] [4] [5] [6] . NMDARs cluster at the core of postsynaptic densities, where they mediate synaptic signaling involved in persistent forms of synaptic plasticity thought to underlie learning and memory [7, 8] . Not surprisingly, NMDARs play a key role in human cognition and behavior. For example, both working and episodic memory rely on NMDAR-regulated networks [9] [10] [11] [12] . The perception of auditory and visual stimuli, even at the early sensory level, is also modulated by NMDARs [13] . As a consequence, pharmacological interventions that interfere with the function of NMDARs result in striking behavioral abnormalities. In healthy volunteers, the NMDARblocking agents phencyclidine and ketamine cause not only impaired working memory and perceptual abnormalities but also other symptoms characteristic of schizophrenic psychosis, such as paranoia, dissociative states, and impaired executive function [14, 15] .
Decreased function of the synaptic NMDARs has also been described in naturally occurring human disorders associated with psychotic symptoms [16, 17] . The most interesting among these disorders, because it is treatable, is produced by IgG autoantibodies targeting the GluN1 subunit of the NMDA receptor [18] . This disorder, which in this opinion article we call NMDAR antibody synaptopathy ( Recently, autoantibodies have been found to cause NMDA receptor hypofunction.
These autoantibodies target the GluN1 subunit of the receptor, internalizing it, and can be detected in the cerebrospinal fluid and, less often, in the sera of affected patients.
These patients have psychotic manifestations in the course of their disease; cerebrospinal fluid was obtained when they worsened, often requiring a respirator.
Despite the severity of their disease they recovered with immunotherapy.
Within in the context of rigorously controlled studies, antibodies against NMDA receptors, or other proteins modulating them, should be sought in the cerebrospinal fluid of patients with schizophrenic or manic psychoses unexplained by psychotropic drug ingestion or other metabolic factors.
